Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children

Li, Sidan, MD; Wu, Runhui, MS; Wang, Bin, BS; Fu, Lingling, MS; Zhu, Guanghua, BS; Zhou, Xuan, BS; Ma, Jie, BS; Zhang, Liqiang, BS; Qin, Maoquan, BS

Journal of Pediatric Hematology/Oncology: January 2019 - Volume 41 - Issue 1 - p 38–41
doi: 10.1097/MPH.0000000000001263
Original Articles

The delay in platelet recovery after hematopoietic stem cell transplantation (HSCT) is closely related to the overall survival rate of transplanted children. The use of platelet-producing agents such as eltrombopag and romiplostim has made great progress in treating diseases such as immune thrombocytopenia and aplastic anemia. However, the use of such drugs in patients with thrombocytopenia after transplantation, especially in children, is rare. This study aimed to report eltrombopag treatment for 3 children with primary platelet engraftment failure and secondary thrombocytopenia after allogeneic HSCT. Of these patients, 2 had platelets stabilized at ≥50×109/L after eltrombopag treatment and subsequent withdrawal of eltrombopag. All 3 patients showed no clear adverse reactions. The results indicated a wide application prospect of eltrombopag treatment in children with thrombocytopenia after allogeneic HSCT.

Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics, Ministry of Education; Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China

Supported by grants from the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Grant (no. ZY201404), the Beijing Municipal Administration of Hospitals DengFeng Program (no. DFL20151101), the National Natural Science Foundation of China (no. 81641006), and Beijing City Youth top-notch talents project (no. 2016000021223ZK16).

The authors declare no conflict of interest.

Reprints: Maoquan Qin, BS, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Department of Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, 56 Nanlishi Road, Beijing 100045, China (e-mail: 18123956@qq.com).

Received February 8, 2018

Accepted June 22, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.